APRE — Aprea Therapeutics, Inc.
Is APRE overbought or oversold? Here is the current MarketMoodz read.
Aprea Therapeutics, Inc. (APRE) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $0.41. The rating moved from Oversold to Strong Oversold on November 17, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$0.41
- Last changeMoved from Oversold to Strong Oversold on November 17, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Aprea Therapeutics is a small-cap biotech with early-stage clinical exposure, limited public visibility and likely ongoing cash burn. The company lacks diversified commercial revenue and faces high execution risk from binary trial outcomes and potential near-term financing needs. Sector themes favor larger, defensive pharma and highlight convertible-debt dilution pressures for smaller issuers — a structural headwind. Near-term upside is primarily tied to positive clinical/regulatory news or strategic transactions, while downside could be accelerated by financing at low prices or adverse trial developments. Given the high information asymmetry and low liquidity, the short-term outlook is volatile with significant downside risk absent a material positive catalyst.
Key factors
- Limited market capitalization and thin liquidity increase volatility and execution risk for investors
- Unproven or early-stage clinical assets with binary trial outcomes that can cause large move swings
- Likely ongoing cash burn and need for near-term financing that can dilute existing shareholders
- Sector-level headwinds for small/mid-cap biotech, including convertible-debt pressure and investor preference for large-cap pharma
- Lack of meaningful social/research coverage and sparse public disclosure increases information asymmetry
- Absence of clear near-term commercial revenue or diversified product portfolio to offset R&D risk
Risks
- Positive clinical trial readouts or regulatory progress that materially re-rate the stock upward
- Strategic partnership, licensing, or acquisition interest that could provide non-dilutive capital or premium valuation
- Unexpected cash infusion, larger-than-expected grant or milestone payment improving the near-term liquidity profile
- Broader biotech risk-on market rallies which disproportionately lift small-cap names
- Further equity or convertible debt financings that dilute shareholders and exert downward pressure if executed at low prices
- Clinical setbacks, adverse safety signals, or regulatory delays increasing downside
- Limited analyst coverage and thin liquidity amplifying price moves on modest news
See today's live rating, score and targets
Members see the live hourly rating for APRE — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.